| 000 | 01753 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250514073936.0 | ||
| 264 | 0 | _c20030923 | |
| 008 | 200309s 0 0 eng d | ||
| 022 | _a0304-3835 | ||
| 024 | 7 |
_a10.1016/s0304-3835(03)00104-6 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJikai, J | |
| 245 | 0 | 0 |
_aNeuroblastoma directed therapy by a rational prodrug design of etoposide as a substrate for tyrosine hydroxylase. _h[electronic resource] |
| 260 |
_bCancer letters _cJul 2003 |
||
| 300 |
_a219-24 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Phytogenic _xpharmacology |
| 650 | 0 | 4 | _aBiotransformation |
| 650 | 0 | 4 | _aBlotting, Western |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 | _aChromatography, High Pressure Liquid |
| 650 | 0 | 4 |
_aDihydroxyphenylalanine _xmetabolism |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 |
_aEscherichia coli _xenzymology |
| 650 | 0 | 4 |
_aEtoposide _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 |
_aNeuroblastoma _xdrug therapy |
| 650 | 0 | 4 | _aPlasmids |
| 650 | 0 | 4 |
_aProdrugs _xchemical synthesis |
| 650 | 0 | 4 | _aSubstrate Specificity |
| 650 | 0 | 4 | _aTumor Cells, Cultured |
| 650 | 0 | 4 |
_aTyrosine _xmetabolism |
| 650 | 0 | 4 |
_aTyrosine 3-Monooxygenase _xgenetics |
| 700 | 1 | _aShamis, M | |
| 700 | 1 | _aHuebener, N | |
| 700 | 1 | _aSchroeder, U | |
| 700 | 1 | _aWrasidlo, W | |
| 700 | 1 | _aWenkel, J | |
| 700 | 1 | _aLange, B | |
| 700 | 1 | _aGaedicke, G | |
| 700 | 1 | _aShabat, D | |
| 700 | 1 | _aLode, H N | |
| 773 | 0 |
_tCancer letters _gvol. 197 _gno. 1-2 _gp. 219-24 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0304-3835(03)00104-6 _zAvailable from publisher's website |
| 999 |
_c12658112 _d12658112 |
||